Clinical Trial Update: 3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China

View source ↗

Summary

This document updates immunogenicity results from a 3-year study of the quadrivalent HPV vaccine in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anogenital Human Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: Guangxi Center for Disease Control and Prevention | Conditions: Anogenital Human Papilloma Virus Infection | Status: UNKNOWN